Platelet Reactivity and Fibrin Clot-Strength as assessed by TEG in Patients with Atrial Fibrillation undergoing Percutaneous Coronary Intervention

2023 ESC Guidelines for the management of acute coronary syndromes | European Heart Journal | Oxford Academic [Internet]. [cited 2024 Oct 20];Available from: https://academic.oup.com/eurheartj/article/44/38/3720/7243210?login=false.

Steensig K, Olesen KKW, Thim T, Nielsen JC, Jensen SE, Jensen LO, Kristensen SD, Bøtker HE, Lip GYH, Maeng M. Should the presence or extent of coronary artery disease be quantified in the CHA2DS2-VASc score in atrial fibrillation? A report from the western denmark heart registry. Thromb Haemost. 2018;118:2162–70.

Article  PubMed  Google Scholar 

Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, Castella M, Diener H-C, Heidbuchel H, Hendriks J, Hindricks G, Manolis AS, Oldgren J, Popescu BA, Schotten U, Van Putte B, Vardas P, Agewall S, Camm J, Baron Esquivias G, Budts W, Carerj S, Casselman F, Coca A, De Caterina R, Deftereos S, Dobrev D, Ferro JM, Filippatos G, Fitzsimons D, Gorenek B, Guenoun M, Hohnloser SH, Kolh P, Lip GYH, Manolis A, McMurray J, Ponikowski P, Rosenhek R, Ruschitzka F, Savelieva I, Sharma S, Suwalski P, Tamargo JL, Taylor CJ, Van Gelder IC, Voors AA, Windecker S, Zamorano JL, Zeppenfeld K. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Eur Pacing Arrhythm Card Electrophysiol J Work Groups Card Pacing Arrhythm Card Cell Electrophysiol Eur Soc Cardiol. 2016;18:1609–78.

Google Scholar 

Van Gelder IC, Rienstra M, Bunting KV, Casado-Arroyo R, Caso V, Crijns HJGM, De Potter TJR, Dwight J, Guasti L, Hanke T, Jaarsma T, Lettino M, Løchen M-L, Lumbers RT, Maesen B, Mølgaard I, Rosano GMC, Sanders P, Schnabel RB, Suwalski P, Svennberg E, Tamargo J, Tica O, Traykov V, Tzeis S, Kotecha D, ESC Scientific Document Group. ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): Developed by the task force for the management of atrial fibrillation of the European Society of Cardiology (ESC), with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Endorsed by the European Stroke Organisation (ESO). Eur Heart J. 2024;45:3314–3414.

Vrints C, Andreotti F, Koskinas KC, Rossello X, Adamo M, Ainslie J, Banning AP, Budaj A, Buechel RR, Chiariello GA, Chieffo A, Christodorescu RM, Deaton C, Doenst T, Jones HW, Kunadian V, Mehilli J, Milojevic M, Piek JJ, Pugliese F, Rubboli A, Semb AG, Senior R, ten Berg JM, Van Belle E, Van Craenenbroeck EM, Vidal-Perez R, Winther S, ESC Scientific Document Group. ESC Guidelines for the management of chronic coronary syndromes: Developed by the task force for the management of chronic coronary syndromes of the European Society of Cardiology (ESC) Endorsed by the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2024;45:3415–3537.

Gurbel PA, Bliden KP, Navickas IA, Mahla E, Dichiara J, Suarez TA, Antonino MJ, Tantry US, Cohen E. Adenosine diphosphate–induced platelet-fibrin clot strength: a new thrombelastographic indicator of long-term poststenting ischemic events. Am Heart J. 2010;160:346–54.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gruttemeier J, Cottin Y, Yao H, De Maistre E, Maza M, Bonello L, Laine M, Resseguier N, Zeller M, Camoin-Jau L, Paganelli F. Impact of platelet reactivity in ACS patients on clinical outcomes with triple antithrombotic therapy. J Clin Med. 2021;10:1565.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rilinger J, Meyer M, Schnabel K, Weik P, Charlet A, Esser JS, Zhou Q, Bode C, Moser M, Diehl P, Olivier CB. High platelet reactivity after P2Y12-inhibition in patients with atrial fibrillation and coronary stenting. J Thromb Thrombolysis. 2016;42:558–65.

Article  CAS  PubMed  Google Scholar 

Sibbing D, Aradi D, Jacobshagen C, Gross L, Trenk D, Geisler T, Orban M, Hadamitzky M, Merkely B, Kiss RG, Komócsi A, Dézsi CA, Holdt L, Felix SB, Parma R, Klopotowski M, Schwinger RHG, Rieber J, Huber K, Neumann F-J, Koltowski L, Mehilli J, Huczek Z, Massberg S, Parma R, Parma Z, Lesiak M, Komosa A, Huczek Z, Koltowski L, Kowara M, Rymuza B, Klopotowski M, Malek L, Aradi D, Veress G, Dézsi AD, Merkely B, Lux Á, Kiss RG, Papp J, Kovács A, Dézsi CA, Amer S, Ruzsa Z, Róna S, Komócsi A, Ili R, Ungi I, Nagy F, Zweiker R, Tóth-Gayor G, Huber K, Haller P, von Scheidt W, Blüthgen A, Neumann F-J, Trenk D, Leggewie S, Kreider-Stempfle HU, Remp T, Kara K, Mügge A, Wutzler A, Fichtlscherer S, Zeiher AM, Seeger F, Hinterseer M, König A, Lederle S, Jacobshagen C, Czepluch F, Maier L, Schillinger W, Sossalla S, Hummel A, Felix S, Karakas M, Sydow K, Rudolph T, Halbach M, Gori T, Münzel T, May A, Gerstenberg C-M, Pilecky D, Rieber J, Deichstetter M, Sibbing D, Mehilli J, Gross L, Kääb S, Löw A, Orban M, Orban M, Sattler S, Deuschl S, Teupser D, et al. Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial. Lancet. 2017;390:1747–57.

Article  CAS  PubMed  Google Scholar 

Hou X-M, Han W-Z, Qiu X-B, Fang W-Y. Clinical characteristics associated with high on-treatment platelet reactivity of patients undergoing PCI after a 300 mg loading dose of clopidogrel, measured by thrombelastography. Heart Asia. 2013;5:66–9.

Article  PubMed  PubMed Central  Google Scholar 

Kwon O, Ahn J-H, Koh J-S, Park Y, Hwang SJ, Tantry US, Gurbel PA, Hwang J-Y, Jeong Y-H. Platelet-fibrin clot strength and platelet reactivity predicting cardiovascular events after percutaneous coronary interventions. Eur Heart J. 2024;45:2217–31.

Article  CAS  PubMed  Google Scholar 

Li Y, Chang H, Ni L, Xue P, Li C, Yuan L, Cui H, Yu C. Analysis of thrombelastogram-guided medication in patients with coronary heart disease after percutaneous coronary intervention. Exp Ther Med [Internet]. 2019 [cited 2022 May 19];Available from: http://www.spandidos-publications.com/10.3892/etm.2019.7294.

Lopes RD, Heizer G, Aronson R, Vora AN, Massaro T, Mehran R, Goodman SG, Windecker S, Darius H, Li J, Averkov O, Bahit MC, Berwanger O, Budaj A, Hijazi Z, Parkhomenko A, Sinnaeve P, Storey RF, Thiele H, Vinereanu D, Granger CB, Alexander JH. Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation. N Engl J Med. 2019;380:1509–24.

Article  CAS  PubMed  Google Scholar 

Hicks KA, Mahaffey KW, Mehran R, Nissen SE, Wiviott SD, Dunn B, Solomon SD, Marler JR, Teerlink JR, Farb A, Morrow DA, Targum SL, Sila CA, Hai MTT, Jaff MR, Joffe HV, Cutlip DE, Desai AS, Lewis EF, Gibson CM, Landray MJ, Lincoff AM, White CJ, Brooks SS, Rosenfield K, Domanski MJ, Lansky AJ, McMurray JJV, Tcheng JE, Steinhubl SR, Burton P, Mauri L, O’Connor CM, Pfeffer MA, Hung HMJ, Stockbridge NL, Chaitman BR, Temple RJ. 2017 cardiovascular and stroke endpoint definitions for clinical trials. Circulation. 2018;137:961–72.

Article  PubMed  Google Scholar 

Schulman S, Kearon C. Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost JTH. 2005;3:692–4.

Article  CAS  PubMed  Google Scholar 

Sibbing D, Aradi D, Alexopoulos D, Ten Berg J, Bhatt DL, Bonello L, Collet J-P, Cuisset T, Franchi F, Gross L, Gurbel P, Jeong Y-H, Mehran R, Moliterno DJ, Neumann F-J, Pereira NL, Price MJ, Sabatine MS, So DYF, Stone GW, Storey RF, Tantry U, Trenk D, Valgimigli M, Waksman R, Angiolillo DJ. Updated expert consensus statement on platelet function and genetic testing for guiding P2Y12 receptor inhibitor treatment in percutaneous coronary intervention. JACC Cardiovasc Interv. 2019;12:1521–37.

Article  PubMed  Google Scholar 

Buckley MS, Benanti GE, Meckel J, Tekle LA, Gilbert B, Puebla Neira D, McNierney DA, Korkames G, Yerondopoulos M, Park A, O’Hea JA, MacLaren R. Correlation between partial thromboplastin time and thromboelastography in adult critically ill patients requiring bivalirudin for extracorporeal membrane oxygenation. Pharmacotherapy. 2023;43:196–204.

Article  CAS  PubMed  Google Scholar 

Gjermeni D, Vetter H, Szabó S, Anfang V, Leggewie S, Hesselbarth D, Duerschmied D, Trenk D, Olivier CB. Thrombelastography compared with multiple impedance aggregometry to assess high on-clopidogrel reactivity in patients with atrial fibrillation undergoing percutaneous coronary intervention. J Clin Med. 2022;11:4237.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jeong Y-H, Bliden KP, Shuldiner AR, Tantry US, Gurbel PA. Thrombin-induced platelet-fibrin clot strength: relation to high on-clopidogrel platelet reactivity, genotype, and post-percutaneous coronary intervention outcomes. Thromb Haemost. 2014;111:713–24.

Article  CAS  PubMed  Google Scholar 

Gurbel PA, Bliden KP, Guyer K, Cho PW, Zaman KA, Kreutz RP, Bassi AK, Tantry US. Platelet reactivity in patients and recurrent events post-stenting. J Am Coll Cardiol. 2005;46:1820–6.

Article  CAS  PubMed  Google Scholar 

Bae JS, Ahn J-H, Jang JY, Cho SY, Kang MG, Kim K-H, Park HW, Koh J-S, Park Y, Hwang S-J, Kwak CH, Hwang J-Y, Tantry US, Gurbel PA, Jeong Y-H. The impact of platelet–fibrin clot strength on occurrence and clinical outcomes of peripheral artery disease in patients with significant coronary artery disease. J Thromb Thrombolysis. 2020;50:969–81.

Article  CAS  PubMed  Google Scholar 

Myers SP, Dyer MR, Hassoune A, Brown JB, Sperry JL, Meyer MP, Rosengart MR, Neal MD. Correlation of thromboelastography with apparent rivaroxaban concentration: has point-of-care testing improved? Anesthesiology. 2020;132:280–90.

Article  CAS  PubMed  Google Scholar 

Hesselbarth D, Gjermeni D, Szabo S, Siegel PM, Diehl P, Moser M, Bode C, Olivier CB. Time from blood draw to multiple electrode aggregometry and association with platelet reactivity. J Thromb Thrombolysis [Internet]. 2022 [cited 2022 Nov 16];Available from: https://link.springer.com/10.1007/s11239-022-02720-7.

Tang Y-D, Wang W, Yang M, Zhang K, Chen J, Qiao S, Yan H, Wu Y, Huang X, Xu B, Gao R, Yang Y, Yuan X, Ji H, Zhou Z, Liu Z, Chen J, Yuan J, Liu H, Qian J, Hu F, Shao C, Zhao H, Hua Y, Lu J. Randomized comparisons of double-dose clopidogrel or adjunctive cilostazol versus standard dual antiplatelet in patients with high posttreatment platelet reactivity: results of the CREATIVE trial. Circulation. 2018;137:2231–45.

Article  CAS  PubMed  Google Scholar 

Kreutz RP, Schmeisser G, Maatman B, Schaffter A, Sinha A, Der Lohe EV, Breall JA. Fibrin clot strength measured by thrombelastography and outcomes after percutaneous coronary intervention. Thromb Haemost. 2017;117:426–8.

Article  PubMed  Google Scholar 

New interest in fibrinogen as an ischemic risk factor | Journal of Thrombosis and Thrombolysis [Internet]. [cited 2024 Oct 24];Available from: https://link.springer.com/article/10.1007/s11239-024-03024-8.

Hochholzer W, Ruff CT, Mesa RA, Mattimore JF, Cyr JF, Lei L, Frelinger AL, Michelson AD, Berg DD, Angiolillo DJ, O’Donoghue ML, Sabatine MS, Mega JL. Variability of individual platelet reactivity over time in patients treated with clopidogrel. J Am Coll Cardiol. 2014;64:361–8.

Article  PubMed  PubMed Central  Google Scholar 

Comments (0)

No login
gif